Although women who carry BRCA1 or BRCA2 mutations have up to an 85% lifetime risk of breast cancer, the majority choose to forego prophylactic mastectomy, which has been proven to markedly lower breast cancer mortality, and opt for lifelong intensive surveillance. Whether surveillance lowers breast cancer mortality in these women is unknown. However, in a formal survey of 34 of these women, 82% indicated a strong belief in the ability of surveillance to find breast cancer at a stage when it is still curable. Since 1997 we have been conducting a study to compare the sensitivity of breast magnetic resonance imaging (MRI), ultrasound, mammography and clinical breast examination (CBE) in women at high risk for hereditary breast cancer. Breast cancer incidence rates have been even higher than predicted for this population. The addition of MRI and ultrasound to conventional surveillance with mammography and CBE significantly improves sensitivity, but at the expense of decreased specificity. Two years ago we began a formal study of distress and breast cancer anxiety. A sample of 25 new and ongoing participants in the surveillance study have completed the Hospital Anxiety and Depression Scale together with the Breast Cancer Worry Scale, up to six times per year over a 2-year period. To date there has been no evidence of any impact of intensive surveillance, including false-positive studies, on anxiety, depression or breast cancer worry.
Introduction
Women who have inherited a BRCA1 or BRCA2 mutation face a 45 -85% risk of developing breast cancer and an 11-60% risk of developing ovarian cancer by the age of 70 years. The cancer incidence rates are of clinical significance from the age of 25 or 30 years onwards [1] [2] [3] . Even prior to considering genetic testing, many women who are eligible for such testing have had to deal with significant psychological stress related to cancer diagnosis and treatment in themselves and/or close relatives. Cancer-related death at a young age in a close relative may be particularly traumatic. The decision whether to undergo genetic testing is very personal and complex. Once a woman is notified that she carries a BRCA gene mutation, she has numerous additional psychological challenges including worry about the vulnerability of herself and her family members to (new) cancers, the burden of disseminating the knowledge to family members and decision-making around prophylactic surgery or chemoprevention.
Psychosocial issues for BRCA mutation carriers
Several years ago our hereditary breast/ovarian cancer team conducted an in-depth survey of our 34 non-metastatic patients who had been given positive genetic results since the beginning of the testing program [4] . The objectives of the study were to determine: (i) the impact of the test results on risk perception and cancer worry; (ii) the mutation carriers' needs (if any) for additional support beyond that provided by routine genetic counseling; and (iii) the attitudes of mutation carriers towards prevention and surveillance options. Eight mutation carriers participated in a 2-h focus group and an additional 16 patients completed a detailed questionnaire that was almost identical to the focus group discussion items. The demographics of the focus group participants, patients who completed the mailed questionnaire and non-participants are summarized in Table 1 . There were no significant differences in responses between the eight focus groups and the 16 questionnaire participants. increase in cancer risk perception to a more appropriate level after receiving positive genetic test results and counseling. Not surprisingly, however, 75% had a significant increase in cancer worry and distress after receiving their genetic test results. These results differ from those reported by Schwartz et al. [5] , who found that at 6 months after disclosure, those who received a positive test result did not exhibit increased psychological distress or perceived risk. This discrepancy may be due to differences between the two patient populations. The patients studied by Schwartz et al. were all self-referred for testing based on their strong family history of breast or ovarian cancer, and already had very high cancer risk perception at baseline. In contrast, more than 90% of the participants in our study were approached for consideration of genetic testing by an investigator who identified them as being at high risk for hereditary cancer.
Need for additional support
A total of 92% of the study participants indicated an interest in ongoing follow-up with the genetic counseling team. Reasons included a desire to receive updates on new research studies or treatments, and an opportunity to have their psychological well-being assessed. In addition, five of the eight focus group participants (62%), and four of the 16 mutation carriers who completed the mailed questionnaire (25%) indicated an interest in a formal support group. Accordingly, in 1999 we joined a multicenter, non-randomized study under the leadership of Dr Mary Jane Esplen, of a 6-month supportiveexpressive group therapy intervention for BRCA mutation carriers. The 70 study participants completed pre and post measures of psychosocial functioning, knowledge and surveillance/surgery activities. The results are in the final stages of analysis and will be submitted for publication within the next few months.
Attitudes towards prevention and surveillance options
Prophylactic oophorectomy was a much more acceptable option than prophylactic mastectomy. While only one patient had undergone prophylactic mastectomy and only six others (27%) were even considering this procedure, 54% had already undergone prophylactic oophorectomy and an additional 32% were seriously considering having this surgery in the future. Surprisingly, study participants expressed high confidence in the ability of lifestyle alterations (e.g. diet, exercise and smoking cessation) and future discoveries in chemoprevention to decrease their cancer risk. Just as surprisingly, 82% of the women expressed a high degree of confidence in the effectiveness of breast surveillance, and 90% of the women who had not undergone prophylactic removal of their ovaries had confidence in the effectiveness of ovarian surveillance. These perceptions stand in stark contrast to the reality that to date there is no firm evidence that any lifestyle intervention or surveillance regimen lowers cancer mortality in BRCA mutation carriers.
Psychological issues pertaining to prophylactic mastectomy
Unlike lifestyle modification and breast surveillance, which may or may not be effective, the ability of bilateral prophylactic mastectomy to markedly reduce breast cancer mortality in BRCA mutation carriers has been established [6] [7] [8] . Nevertheless, this procedure remains unacceptable to the majority of mutation carriers [9 -13] . There are multiple reasons for this, which are summarized in Table 2 . Even in the hands of an excellent reconstructive surgeon, bilateral prophylactic surgery is mutilating surgery that affects both appearance and sensation. Since most mutation carriers who develop breast cancer are candidates for breast conservation, it seems ludicrous to many women to undergo a preventive procedure that is more radical than the treatment of the disease at which the prevention is aimed. For mutation carriers who have already been diagnosed with breast or ovarian cancer, the probability of dying of a new primary breast cancer may be significantly lower than the risk of dying of recurrence of their previous malignancy. Women know that even in the absence of any intervention, not all mutation carriers will develop breast cancer, and that with proven prevention strategies such as prophylactic oophorectomy and tamoxifen, the odds are even better. Many believe that in the not too distant future more effective chemoprevention will be available. Finally, these women know that most breast cancer is curable and have faith that with intensive surveillance, their prognosis will be even more favorable. Several studies have looked at the psychological consequences of prophylactic mastectomy. Except for the most recent reports, the subjects were women whose genetic status was unknown but who underwent the procedure because of a very strong family history of breast cancer or multiple previous benign biopsies. Borgen et al. [14] surveyed 370 women who had undergone bilateral prophylactic mastectomy, a mean of 15 years previously, with breast reconstruction performed in 75%. Only 21 of the women (6%) regretted their decision to have the surgery. In a second study of the long-term satisfaction of American women with prophylactic mastectomy, Frost et al. [15] found that 74% of the 572 study participants reported a drop in breast cancer worry following the surgery. However, 36% reported reduced satisfaction with their body appearance.
Two prospective studies have looked at differences between high-risk women who chose prophylactic mastectomy and those who chose surveillance. In a British study of 143 women, follow-up interviews were conducted at 6 and 18 months. Women who opted for surgery (approximately half) tended to have higher perceived risk at baseline. Psychological morbidity and anxiety, which were high at baseline, declined significantly over time in the women who underwent mastectomy but remained high in the group that opted for surveillance. The women who had surgery maintained a positive body image and reported few or no changes in sexual functioning [16] . In marked contrast, a 1-year study from The Netherlands of 26 documented BRCA1 or BRCA2 mutation carriers found that anxiety and cancer-related distress among the 14 women who opted for surgery declined over time but remained significantly higher than among the women who opted for surveillance. Moreover, they found significant adverse effects among the women who underwent mastectomy (10 of whom also had reconstruction) in terms of perception of body image, the intimate relationship and physical wellbeing [17] .
Psychological impact of breast surveillance for hereditary breast cancer
The current recommendation for surveillance of women known or likely to carry BRCA1 or BRCA2 mutations is monthly breast self-examination, annual or semi-annual clinical breast examination (CBE), and annual mammography beginning at age 25-35 years and continuing indefinitely [18] [19] [20] . Because of the limitations of screening mammography in younger women in general (due to greater breast density), and in BRCA1 mutation carriers in particular (less ductal carcinoma in situ with its characteristic calcification; fleshy, pushing rather than infiltrating margins), there has been great interest in other imaging modalities for screening these women. The two most widely used have been ultrasound and magnetic resonance imaging (MRI), which are both much less affected by breast density than mammography [21] [22] [23] .
In November 1997, we began a surveillance study for women at very high risk for hereditary breast cancer. Annual ultrasound and MRI are added to annual mammography and semi-annual CBE, with all imaging performed on the same day. Suspicious lesions that can only be visualized with MRI are evaluated with MRI-guided needle localization and excisional biopsy. To date, 403 women, of whom 68% are mutations carriers, have enrolled in the study. We have found the sensitivity of MRI to be significantly higher than that of either mammography or ultrasound (with very low sensitivity for CBE) [24] . Similar results were reported by Kuhl et al. [25] , and other groups have all confirmed the superiority of MRI in this setting [26, 27] . The sensitivity of MRI has consistently been reported to be in the range of 75-95%, compared with 35 -45% for mammography. With the exception of the experience of Kuhl's group [28] , the improved sensitivity of MRI has come at the expense of lower specificity, resulting in more unnecessary repeat studies and biopsies [24, 26, 29] . While these results are very encouraging, MRI-based surveillance must still be considered investigational, as it is very costly and has not yet been shown to reduce mortality.
The psychological effects of intensive breast surveillance may be positive, negative or a combination of these. Positive effects include the reassurance provided by frequent contact with the health-care system in general, and by negative screening studies in particular. Negative effects include: the discomfort of screening procedures (breast compression for mammography, the insertion of an intravenous line and claustrophobia for MRI); increased anxiety in the period around screening until negative results are received; and the physical and emotional discomfort of additional procedures generated by false-positive tests.
Women of average breast cancer risk who undergo breast screening do not experience negative psychological consequences unless they have a false-positive study, in which case emotional disturbances may persist for 6 months or more after being informed that the work-up ultimately showed no evidence of breast cancer [30] [31] [32] [33] [34] . One study reported that screening was less stressful for women with a family history than for those without [33] . There is a paucity of information in the literature on the psychological impact of intensive surveillance on BRCA mutation carriers, and extrapolating from the results of studies carried out on screened populations of average risk or women with a non-specific family history, may or may not be appropriate. The situation is further complicated by the fact that, as previously mentioned [16, 17] , mutation carriers who opt for surveillance appear to be a self-selected group with a significantly different psychological profile than carriers who opt for bilateral mastectomy.
In May, 2002 we began a pilot study to assess distress and breast cancer worry in the women participating in our MRIbased breast surveillance study for very high-risk women [24] with or without a previous diagnosis of breast cancer. New participants to the surveillance study, as well as women who had already undergone at least one round of imaging, were eligible. New participants were contacted by telephone 6-8 weeks prior to their first imaging appointment and asked whether they wished to participate in the 'psychological' companion study. Those who agreed to participate in the study were mailed a package containing a consent form and two sets of psychological distress scales with stamped return envelopes, with instructions to complete the first set 1 month before their appointment, and the second set within 48 h before the appointment. At the time of the appointment they were given a third set of questionnaires to be completed 1 month later. Subsequent mailings were sent 3, 6, 9 and 11 months after the surveillance appointment, with instructions to complete the last set of questionnaires within 48 h of the second annual surveillance appointment. Consenting women who were already on the study received their first questionnaire package at the next closest point to the 3, 6, 9 or 11 month interval from their last round of surveillance imaging.
One of the two questionnaires was the Hospital Anxiety and Depression Scale [35, 36] , a 14-item Likert scale that has seven items measuring anxiety and seven measuring depression. It has been extensively used and validated as a measure of distress in hospital and oncology populations, as well as in high-risk women in the UK and in North America. The other questionnaire was the Breast Cancer Worry Scale, a 19-item Likert scale that examines both the intrusive and avoidant thoughts specifically related to breast cancer, as well as the anxiety and fear associated with breast cancer and screening. The scale was developed specifically for use with women with a family history of breast and ovarian cancer who participate in studies of genetic screening. One additional item about MRI-related anxiety was added that had wording otherwise identical to an existing item about mammographyrelated worry. Study participants were also asked whether they had undergone any of a number of specified life events over the previous 3 months, and to elaborate on the emotional impact of these events if they had. The questionnaires could be completed in less than 15 min.
Fifty-seven (95%) of the 60 women approached agreed to participate, and 28 have completed at least one questionnaire. Of these, 25 have completed at least three questionnaires.
The characteristics of these 25 women are summarized in Table 3 . Their demographics are similar to those of the larger population of women on the surveillance study. Over the course of the psychosocial study, 10 (40%) of these women underwent at least one additional imaging procedure because of indeterminate or suspicious findings, and four (16%) underwent at least one biopsy, which in one case was malignant.
Analysis of the results to date demonstrated higher baseline anxiety and breast cancer worry scores in the new recruits to the surveillance study than in women who had already had at least one round of imaging. This may reflect the fact that new recruits had only recently received their genetic test results. This is consistent with the findings of Lodder et al. [17] , who found a decrease in anxiety in mutation carriers who opted for surveillance over the year following test result disclosure. For any individual woman in our study, no significant variability in the scores was seen over the course of the year, with the exception of those women who had significant life events unrelated to breast cancer. Specifically, no effect of additional imaging tests or biopsies could be demonstrated. Although these results are reassuring, they remain very preliminary.
In summary, BRCA mutation carriers who opt for breast surveillance rather than prophylactic mastectomy are a selfselected group with generally lower breast cancer-related anxiety levels. While preliminary results suggest that anxiety in this group tends to decrease further over the year following test result disclosure, there may be a significant minority of individuals who react otherwise. Long-term studies of women receiving intensive breast surveillance are clearly needed to determine whether there are cumulative detrimental psychological effects over time, especially in women who have repeated false-positive tests. It is also not clear how these women will cope with a future diagnosis of breast cancer after many years of normal surveillance studies. 50% probability of being carrier 3 (12) i46
